Global Patent Index - EP 2370060 B1

EP 2370060 B1 20170503 - HYDROPHOBINS AS SURFACE ACTIVE PROTEINS AS EXCIPIENTS IN SOLID PHARMACEUTICAL FORMULATIONS

Title (en)

HYDROPHOBINS AS SURFACE ACTIVE PROTEINS AS EXCIPIENTS IN SOLID PHARMACEUTICAL FORMULATIONS

Title (de)

HYDROPHOBINE ALS OBERFLÄCHENAKTIVE PROTEINE ALS HILFSSTOFFE IN FESTEN PHARMAZEUTISCHEN FORMULIERUNGEN

Title (fr)

HYDROPHOBINES COMME PROTÉINES À SURFACE ACTIVE EN TANT QU'EXCIPIENTS DANS DES FORMULATIONS PHARMACEUTIQUES SOLIDES

Publication

EP 2370060 B1 20170503 (EN)

Application

EP 09755883 A 20091113

Priority

  • EP 2009065100 W 20091113
  • EP 08170101 A 20081127
  • EP 09755883 A 20091113

Abstract (en)

[origin: WO2010060811A2] The invention relates to a use of surface active hydrophobins for applications in pharmaceutical technology, in particular as excipients for galenic use. Provided is a method for either admixture of hydrophobins to galenic compositions or for treating the surface of pharmaceutical forms with a hydrophobin-containing solution to modify the pharmaceutical properties of the galenic form. In a preferred embodiment of the invention hydrophobins are used to improve the properties of a pharmaceutical composition, e. g. to act as a surfactant or to increase resistance to disintegration of the galenic forms to achieve a retarded drug release. The galenic form to be modified by the use of surface active proteins as excipients can be capsules, tablets, pills, microparticles, vesicles, and suppositories, although further galenic forms are envisioned. The surface active proteins used for the purpose of present invention can either be isolated from their respective natural source or prepared by recombinant techniques and expression in a suitable host.

IPC 8 full level

A61K 9/20 (2006.01); A61K 9/00 (2006.01); A61K 9/28 (2006.01); C07K 14/37 (2006.01)

CPC (source: EP KR US)

A61K 9/0053 (2013.01 - EP); A61K 9/0065 (2013.01 - US); A61K 9/20 (2013.01 - KR); A61K 9/2063 (2013.01 - EP US); A61K 9/2095 (2013.01 - EP US); A61K 9/28 (2013.01 - KR); A61K 9/2873 (2013.01 - EP US); A61K 9/2893 (2013.01 - EP); A61K 9/4891 (2013.01 - EP US); A61P 39/00 (2017.12 - EP); C07K 14/37 (2013.01 - EP KR US)

Citation (examination)

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DOCDB simple family (publication)

WO 2010060811 A2 20100603; WO 2010060811 A3 20101021; AU 2009319183 A1 20110721; AU 2009319183 B2 20140605; CA 2750421 A1 20100603; CA 2750421 C 20161018; CN 102227215 A 20111026; EP 2370060 A2 20111005; EP 2370060 B1 20170503; JP 2012509921 A 20120426; KR 20110089432 A 20110808; US 2011268792 A1 20111103; US 8226967 B2 20120724; ZA 201104614 B 20120926

DOCDB simple family (application)

EP 2009065100 W 20091113; AU 2009319183 A 20091113; CA 2750421 A 20091113; CN 200980147522 A 20091113; EP 09755883 A 20091113; JP 2011537925 A 20091113; KR 20117014304 A 20091113; US 200913130128 A 20091113; ZA 201104614 A 20110622